NTLA
Intellia·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NTLA
Intellia Therapeutics, Inc.
A leading developer of in vivo genome editing therapies using CRISPR technology
40 Erie Street
, Suite 130
, Cambridge
, Massachusetts 02139
--
Intellia Therapeutics, Inc., was incorporated in Delaware in May 2014. The company is a leading gene editing company focused on the development of unique, potentially curative therapies using a recently developed systematic biological tool known as CRISPR/Cas 9. The company believes that the CRISPR/Cas9 technology has the potential to modify drugs in the human body by permanently editing disease-associated genes with a single course of treatment. The company intends to use its leading scientific expertise, clinical development experience and intellectual property position to unlock the broad therapeutic applications of CRISPR/Cas9 gene editing and develop a new generation of therapeutic products with potential.
Earnings Call
Q1/2025
Estimate EPS-1.27
Actual EPS-1.1
Estimate Revenue11.99M
Actual Revenue16.63M
Contradictions in Clinical Trials: A Deep Dive into ATTR CM and HAELO Study Progress
May 19,2025 09:03
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-1.01
Actual EPS-0.98
Estimate Revenue12.16M
Actual Revenue14.24M
Intellia Therapeutics' Q2 2025: Key Contradictions in MERIT Trial Expansion, Cash Runway, and Clinical Study Timelines
Aug 07,2025 05:32
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
NTLA has released its 2025 Q3 earnings. EPS was reported at -0.92, versus the expected -0.98, beating expectations. The chart below visualizes how NTLA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NTLA has released its 2025 Q3 earnings report, with revenue of 13.78M, reflecting a YoY change of 51.27%, and net profit of -101.32M, showing a YoY change of 25.34%. The Sankey diagram below clearly presents NTLA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
